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A workshop of experts from France, Germany, Italy, and the United States took place 
at Humanitas Research Hospital Milan, Italy, on February 10 and 11, 2016, to examine 
techniques for and applications of robotic surgery to thoracic oncology. The main topics 
of presentation and discussion were robotic surgery for lung resection; robot-assisted 
thymectomy; minimally invasive surgery for esophageal cancer; new developments in 
computer-assisted surgery and medical applications of robots; the challenge of costs; 
and future clinical research in robotic thoracic surgery. The following article summarizes 
the main contributions to the workshop. The Workshop consensus was that since 
video-assisted thoracoscopic surgery (VATS) is becoming the mainstream approach 
to resectable lung cancer in North America and Europe, robotic surgery for thoracic 
oncology is likely to be embraced by an increasing numbers of thoracic surgeons, since 
it has technical advantages over VATS, including intuitive movements, tremor filtration, 
more degrees of manipulative freedom, motion scaling, and high-definition stereoscopic 
vision. These advantages may make robotic surgery more accessible than VATS to 
trainees and experienced surgeons and also lead to expanded indications. However, 
the high costs of robotic surgery and absence of tactile feedback remain obstacles to 
widespread dissemination. A prospective multicentric randomized trial (NCT02804893) 
to compare robotic and VATS approaches to stages I and II lung cancer will start shortly.
Keywords: robotic surgery, lung cancer, segmentectomy, virtual reality, cost–benefit analysis
iNtrODUctiON
The first day of the Workshop consisted mainly presentations and discussions in the broad areas of 
future evolution of medical robotics, costs, current situation of robotics in thoracic surgery, and research 
perspectives in robotic thoracic surgery. The second day was mainly concerned with the presentation 
of live surgery sessions, with ample time for questions and discussion.
rOBOtic sUrGerY FOr LUNG resectiONs
Thoracic surgeons should only consider starting to use a robot if they are enthusiastic about the 
technique: the fact that the hospital has bought robots and was setting up a robot unit is not suf-
ficient reason for getting involved. Thoracic surgeons should be enthusiastic about robotic surgery 
2Veronesi et al. Update on Robotic Thoracic Surgery
Frontiers in Oncology | www.frontiersin.org October 2016 | Volume 6 | Article 214
because of its high-definition visibility, greater independence, 
and easier more intuitive movements compared to video-assisted 
thoracoscopic surgery (VATS). In addition, robotic surgery has 
advantages for the patient. These are similar to those afforded by 
VATS (1) and include reduced pain, fewer complications, and 
shorter postoperative stay than thoracotomy, with equivalent 
oncological outcomes.
Disadvantages of robotic surgery are high capital costs, steep 
learning curve for the entire surgical team, inability to palpate, 
and (often) inability to obtain adequate robotic time in many 
hospitals.
Personal experience of 353 consecutive robotic anatomic lung 
resections was presented. A four-robotic arm technique with 
no access incision was used that differed from the technique 
employed by other groups; it had the advantage that the surgeon 
could assist himself, thereby reducing the variability associated 
with different assistants. Eighty-eight percent of patients had 
a malignancy, from whom a median of 17 lymph nodes was 
removed with median hospital stay of 2  days. Forty-one cases 
were converted to open surgery: 10 for bleeding (1 patient 
required transfusion) but no conversions for bleeding in the last 
100 patients. Thirty-day postoperative mortality was 0.25% and 
90-day mortality was 0.5%. Patients reported a median pain score 
of 2/10 at the 3-week follow-up (2).
As regards the costs of robotic surgery for lung lobectomy, 
an analysis of Medicare patients was made based on the State 
of Alabama’s Medicare reimbursement for lobectomy/segmen-
tectomy of $18,937, which was considerably lower than for most 
other states of the United States. The median hospital charge 
was $32,000 per patient, direct costs were $13,800 per patient, 
so the institutional profit was $4,750 per patient. The calculation 
considered direct costs (items used in patient care) and indirect 
costs (overheads, including cost of the building and amortiza-
tion of capital equipment and supplies, equipment maintenance, 
utilities and administrative staff costs). However, it was difficult 
if not impossible to factor in all contributors to costs (3).
rOBOtic LUNG seGMeNtectOMY
While lobectomy remains the standard for stage I non-small cell 
lung cancer (NSCLC), low-dose CT screening is diagnosing more 
patients with small early-stage disease, who might be adequately 
treated by sublobar resection (4), and this is being investigated by 
ongoing trials (5). Segmentectomy has generally been performed 
by an open approach, and few publications on segmentectomy 
performed by VATS are available because it is a technically 
demanding procedure that until recently was performed by a 
small number of highly experienced groups (6).
However, since the advent of robotic surgery, several papers 
on robotic approaches to segmental dissection have been pub-
lished (7–10). These indicate that robot-assisted thoracoscopic 
segmentectomy for malignant and benign lesions is practical, 
safe, and associated with few complications, short postoperative 
hospitalization, and adequate number of lymph nodes removed.
When performing a segmentectomy with a da Vinci robotic 
system, operating room staff set up the robot console, and the 
visual system. After induction of general anesthesia, the patient 
is placed in lateral decubitus with the hips flexed and secured. 
A double-lumen endotracheal tube is used to ventilate the lung 
not being operated on. The robot is positioned at the head or at 
the side of the patient. The operation begins with a 1-cm incision 
through the eighth intercostal space at the level of the mid-axillary 
line, through which the 30° high-definition stereoscopic camera 
is inserted to explore the thoracic cavity and provide visual guid-
ance for the successive 3-cm utility incision, which is through the 
fourth or fifth intercostal space anteriorly. This is followed by an 
8-mm incision at the eighth intercostal space in the posterior axil-
lary line for the right robotic arm (on the right side) and another 
incision in the auscultatory triangle posterior for the final robotic 
arm. This fourth incision makes it possible to retract the lung 
and therefore better expose the operating field. The camera port 
is placed more laterally for the left side so that the heart does not 
obscure the operating field; otherwise, port placement does not 
vary. Dr. Cariboni went on to describe specific segmentectomies.
rOBOtic LUNG LOBectOMY WitH 
LYMPH NODe DissectiON
Robotic lobectomy plus lymph node dissection for lung cancer is 
performed in Milan using a four-arm system – three robot arm 
ports and a utility incision (mainly to remove the specimen) and 
no CO2 insufflation. To be eligible for robotic lobectomy patients 
had to have adequate cardiopulmonary reserve and a resectable 
lesion. The same extensive staging as for open surgery is per-
formed (10, 11). The patient is positioned in lateral decubitus and 
single-lung anesthesia induced via a double-lumen endotracheal 
tube. The da Vinci Si robot is positioned slightly behind the 
patient’s head, while the da Vinci Xi robot is positioned lateral 
to the patient. Port positions are as described for segmentectomy 
and are standard for all lobectomies except that on the right side, 
the camera port through the seventh intercostal space is in the 
mid-axillary line, whereas on the left side, this port is moved 2 cm 
posteriorly so that the heart does not obscure vision of hilar struc-
tures. Lobectomy begins by isolating hilar elements from anterior 
to posterior using a hook and two Cadière graspers. One is used 
to retract the lung and expose structures; the other, manipulated 
by the left arm of the robot, and used to grip structures during 
dissection, is introduced through the utility incision for left side 
lobectomies or through the posterior eighth intercostal space port 
for right side lobectomies. Blood vessels and the bronchus are sec-
tioned using mechanical staplers introduced by the assistant after 
removal of a robotic arm. The pulmonary vein is usually the first 
structure to be isolated and divided. If the lesion is in the right 
upper lobe, vein resection is followed by isolation of the branches 
of the pulmonary artery and sectioning, followed by isolation 
of the bronchus and bronchus sectioning. If the lesion is in the 
right lower lobe or left lung, after pulmonary vein sectioning, the 
bronchus is usually isolated and stapled before the artery. When 
performing middle lobectomy, the most favorable sequence is 
vein, bronchus, and artery.
Suspicious lymph nodes are usually removed before lobec-
tomy, but radical lymph node dissection is performed after lobec-
tomy. Paratracheal lymph node dissection is performed on the 
right side without azygos vein division. The mediastinal pleura 
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between the superior vena cava and the azygos vein is incised. 
The lymph nodes, together with the fatty soft tissue of the right 
paratracheal space, are removed en bloc using a hook and Cadière 
grasper. In patients with large quantities of mediastinal fat or very 
large lymph nodes, an UltraCision harmonic scalpel is often used.
The nodes of the subcarinal station are removed after resection 
of the pulmonary ligament and retraction of the lung toward the 
anterior mediastinum, to expose the posterior mediastinum. 
Bronchial arteries are usually avoided without difficulty thanks 
to good visibility; otherwise, they can be coagulated. TachoSil 
sealant is sometimes applied to the fissure surface to reduce air 
leakage. A single 28 Ch pleural drain is positioned at the end of 
the operation.
While lymphadenectomy with VATS can be suboptimal 
and challenging (12), it is relatively easy to perform a radical 
dissection of the mediastinal and hilar lymph nodes using the 
robot (13).
rOBOt-AssisteD tHYMectOMY
Radical total thymectomy is the most effective means of achiev-
ing long-term remission in many patients with myasthenia gravis 
(MG) and is the standard treatment for localized thymoma. Since 
MG commonly affects young women, less invasive transcervical 
approaches were developed early, in opposition to transsternal 
approaches. The introduction of robotic-assisted thymectomy is 
rendering both these approaches obsolete. The first robotic exci-
sion of a thymoma was performed in 2001, since then, robotic 
thymectomy as treatment for thymoma and MG has expended 
rapidly. Over 100 centers worldwide perform robotic thymec-
tomies, and approximately 3,500 robotic thymectomies were 
performed between 2001 and 2012 (14). MG remission rates and 
thymoma recurrence rates are comparable to those obtained with 
open procedures and perioperative complication rates are low 
(below 2%) (15). The group at the Charité University of Medicine 
in Berlin developed a widely used three-trocar unilateral robot-
assisted thymectomy using the da Vinci robot system (14), in 
which all three trocars are placed along the submammary fold in 
women. Benefits for patients who undergo robotic thymectomy 
include the unilateral as opposed to bilateral approach of VATS 
(16) and the higher remission rates after robotic procedures than 
VATS (14).
MiNiMALLY iNvAsive sUrGerY FOr 
esOPHAGeAL cANcer
Technical aspects of robotic esophagectomy were discussed, illus-
trated by video recordings showing details of port placement and 
the operation itself (17). Outcomes for 85 consecutive esophageal 
cancer patients were presented. These patients were scheduled 
for minimally invasive Ivor Lewis esophagectomy (laparoscopic 
or robotic abdominal and robotic chest). Sixty-four patients 
(75%) had preoperative chemoradiotherapy, 99% had esophageal 
cancer, and 99% had an R0 resection. There were no abdominal 
or thoracic conversions for bleeding. There was one abdominal 
conversion for inability to completely staple the gastric conduit. 
Mean operating time was about 6 h, median blood loss was 35 ml 
(no intraoperative transfusions), median number of resected 
lymph nodes was 22, and median length of stay was 8  days. 
Conduit complications (anastomotic leak or conduit ischemia) 
occurred in six patients. Thirty-day and 90-day mortalities 
were 3.5 and 10.6%, respectively. Poor initial results resulted in 
longer rehabilitation prior to surgery, liver biopsy in patients 
with suspected cirrhosis, and refinements to conduit preparation 
and anastomotic technique. Mortality was nevertheless disap-
pointingly high, perhaps in part because of the high proportion 
who received induction chemoradiotherapy, although a previous 
report had 5.3% postoperative mortality in patients receiving 
induction therapy (18). It is also noteworthy that 30-day mortal-
ity was 0% and 90-day mortality was 7.1% for the last third of the 
series, so surgeon experience may have played a role.
MiNiMALLY iNvAsive esOPHAGectOMY 
FOr cANcer
Radical esophagectomy for cancer carries high risks of postop-
erative morbidity and mortality, since it requires violating both 
the abdominal and thoracic cavities. Recent case series, system-
atic reviews, and meta-analyses (19–21) clearly indicate that 
minimally invasive approaches to esophagectomy for cancer are 
associated with reduced in-hospital mortality, reduced incidence 
of pulmonary complications, lower intensive care requirements, 
shorter duration of hospital stay, reduced pain, and at least similar 
oncological outcomes to open surgery.
A randomized trial comparing quality of life and late complica-
tions in minimally invasive esophagectomy and open esophagec-
tomy groups (22) showed, a year after surgery, that the physical 
health composite of the SF36 instrument, global health of the 
EORTC C30 questionnaire, and pain in the OES 18 questionnaire 
were significantly better in the minimally invasive group, while 
there were no differences in 1-year survival or complications. On 
the negative side, surgeons needed to be highly experienced in 
both esophageal surgery and minimally invasive techniques in 
order to obtain good results, and operating times were longer 
for minimally invasive than open surgery. Notwithstanding this, 
30% of esophageal resections were recently reported a being per-
formed using a minimally invasive approach (23). A 2015 paper 
from Palazzo et al. (24) compared a contemporary series of 104 
patients who received minimally invasive esophagectomy, with 
68 patients who received either open or hybrid esophagectomy 
from 2000 to 2013. The groups were of similar age and sex distri-
bution. The minimally invasive esophagectomy group had lower 
operative mortality (3.9 versus 8.8%, p = 0.35) and significantly 
fewer major complications. Five-year survival was 64% in the 
minimally invasive group and 35% in the open group (p < 0.001). 
Multivariate analysis adjusted for covariates showed significantly 
worse survival in the open group.
These findings are in line with those of a 2015 paper from the 
UK (25), which used multivariate analysis to compare 83 patients 
given open esophagectomy, 187 patients given hybrid esophagec-
tomy, and 64 patients given minimally invasive esophagectomy. 
Factors that correlated independently and significantly with 
survival were stage, nodal status, and type of operation (with 
minimally invasive patients surviving longer).
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Taken together, these data suggest that totally minimally inva-
sive esophagectomy is superior in several respects to open and 
hybrid techniques. However, even in many high volume centers, 
minimally invasive Ivor Lewis esophagectomy does not appear to 
be the technique of choice, perhaps because of difficulties with the 
anastomoses. For two-hole minimally invasive esophagectomy, 
several anastomotic techniques have been described including 
semi-mechanical anastomosis with a linear stapler and mechani-
cal anastomosis with a circular stapler and a double-stapling tech-
nique. No technique appears superior, but good results have also 
been reported for anastomoses performed robotically, suggesting 
that availability of a robot might encourage more widespread use 
of minimally invasive esophagectomy.
iNterNAtiONAL NetWOrK FOr 
rOBOtic tHOrAcic sUrGerY
Proposals for an international network of robotic thoracic sur-
geons were presented. The network, to be called Robotic Chest 
Surgeons Network (ROCS-NET) aims to promote the safe use 
of robotic equipment in thoracic surgery, in a context in which 
many surgeons still prefer open posterolateral or muscle-sparing 
thoracotomies, because of the disadvantages to the surgeon of 
performing VATS. Robotic surgery has several advantages (intui-
tive movements, tremor filtration, more degrees of manipulative 
freedom, motion scaling, high-definition stereoscopic vision, 
stable camera platform, equivalence between dominant and 
non-dominant hands, and eye–hand–target alignment) (11–17) 
that should make it more accessible than VATS, both to trainees 
and experienced thoracic surgeons, and also expand indications. 
Furthermore, new and improved robotic devices are likely to 
become available soon, encouraging the expansion of robotic 
surgery and hopefully reducing costs.
The Robotic Chest Surgeons Network will be concerned with 
surgeon training and quality control so as to minimize complica-
tions during learning, including in particular: (a) standardization 
and certification of training; (b) monitoring adverse events and 
developing quality performance measures; (c) holding master 
classes to train young thoracic surgeons in robotic skills; (d) data 
sharing (common database) and facilitating clinical research; and 
(e) fostering a climate of cooperation to encourage researchers to 
exchange ideas and design trials.
The Network will also contribute to the development of tho-
racic health care policies.
Few organizations concerned specifically with robotic surgery 
exist. One of the most important is the Clinical Robotic Surgical 
Association (CRSA) founded in Chicago in 2008. However, this 
society does not attract enough European thoracic surgeons 
because it mainly focuses on abdominal diseases and because 
most of its conferences are held in the US. ROCS-NET is spe-
cifically aimed at thoracic surgeons, at all levels, specializing in 
robotic surgery.
ROCS-NET will incorporate and develop an autonomous 
nodes network (ANN) – an information system in which every 
node in the network is autonomous (responsible for its own data), 
overcoming the fear that many investigators have of loosing con-
trol of their data when they enter multicenter studies, although 
it can share data with the other nodes. ANN in fact would be 
a decentralized IT system that encourages spontaneous studies 
from individual participating centers.
tHe cOsts OF rOBOtic sUrGerY
Experience of robotic surgery at the Pisa Multidisciplinary Robotic 
Center was analyzed. The Center was set up in 2009 and by 2015 
had 36 surgeons performing 38 types of surgical procedure, using 
three da Vinci robots. A thousand robotic surgical procedures 
were performed in 2015. Management’s aim was to achieve 
sustainability based on high surgical volumes, the performance 
of complex procedures, and standardization. To identify ways 
of achieving greater efficiency, intensive monitoring of activity 
was undertaken which resulted in major modifications to work-
ing practice. A Bill of Materials (BoM) was generated for every 
surgical procedure performed by each surgeon so as to identify 
all items of cost and also variations in behavior. Implementation 
of protocols helped to effectively contrast unnecessary variations 
in practice and achieve standardization.
After 6 years of experience, positive effects of standardization 
and monitoring using the BoM system had become evident, and 
for some robotic surgical procedures (including lung lobectomy) 
analyses that considered revenues from disease-related groups 
(DRGs) and total activities-based costs, indicated that the Center 
was making a profit.
It was found that savings were not obtained directly from 
innovation but by using innovation as a starting point to stimu-
late more efficient organization. As a university and academic 
hospital, there was a natural propensity to innovate, which helped 
the hospital to better meet the needs of the public. The Center 
was also using surgical robotic as an integral part of its surgeon 
training programs.
rOBOtic sUrGerY versUs vAts 
FOr MAJOr LUNG resectiONs: 
A PrOsPective rANDOMiZeD triAL
A randomized trial (NCT02804893) to compare VATS with 
robotic surgery for lung resections to treat lung cancer is about 
to start recruiting. VATS is an established approach to resectable 
lung cancer, being associated with reduced pain, fewer compli-
cations, shorter postoperative stay, and equivalent oncological 
outcomes compared to thoracotomy (1, 26). Furthermore, its use 
is expanding rapidly: in 2015, 50% of the pulmonary lobectomies 
performed in the United States, and 33% of those performed in 
Europe employed a minimally invasive approach (27) However, 
because of restricted freedom of movement and poor ergonom-
ics, VATS is demanding for thoracic surgeons and requires a long 
learning curve.
In theory, robotic surgery overcomes many of the disadvan-
tages of VATS, but these benefits have not been conclusively 
demonstrated. A recent large retrospective comparison of the 
two techniques (28) found that for robotic lobectomy and wedge 
resection, costs were higher and operating times longer than for 
VATS, with no difference in adverse events. However, 40 robotic 
centers were included in the evaluation – an average of 8 robotic 
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cases per center, suggesting that many of the surgeons may still 
have been learning the robotic technique.
A smaller 2015 comparison (29) of the first 28 VATS lobecto-
mies with the first 28 robotic lobectomies performed in a single 
institution reported that perioperative outcomes were similar for 
both techniques during the learning period but that the robotic 
approach was associated with better safety and fewer conversions 
for uncontrolled bleeding.
NCT02804893 is a prospective multicentric randomized trial 
to compare complications and conversion rates between robotic 
and VATS approaches to stage I and II lung cancer. It is being 
coordinated by Humanitas Research Hospital, Rozzano, Italy, and 
so far, institutes from Istanbul, Marseilles, Strasburg, and Florida 
have indicated their willingness to join. The primary endpoint is a 
combination of adverse events (intraoperative and postoperative 
complications, conversions). Secondary endpoints are duration 
of surgery, number of resected lymph nodes, hospital stay, pain, 
quality of life, immune response, and respiratory function. 
Inclusion criteria are age >18  years, known or suspected lung 
cancer, clinical stage T1–T2, N0–N1, patient candidate for lobec-
tomy or anatomical segmentectomy, and good general condition 
(American Society of Anesthesiologists Physical Status I or II). 
Exclusion criteria are metastatic cancer, extrapulmonary primary 
cancer, severe heart disease, alcohol abuse, renal impairment, or 
presence of other serious comorbidities.
Any intraoperative/perioperative complication or conversion 
will be regarded as a failure of surgery. The trial will need to 
recruit 150 patients per arm to have an 80% power (5% sig-
nificance level) to demonstrate a reduction of 15% in surgery 
failures, assuming 35% failures with VATS and 20% with robotic 
surgery. This sample size also has 80% power to detect a 15% 
reduction in operating time (from 210 to 180 min), 95% power 
to detect a difference in blood loss, and 95% power to detect a 
difference in mean number of mediastinal lymph node stations 
dissected.
NeW DeveLOPMeNts iN  
cOMPUter-AssisteD sUrGerY
Promising new developments in computer-assisted surgery rely 
on modern imaging technology in combination with virtual 
reality and augmented reality. Three main steps are involved: 
(a) obtaining a 3D model of the patient’s anatomy from his/her 
CT or MRI scans; (b) use of this patient-specific model (virtual 
reality model) for preoperative surgical planning and surgical 
simulations; and (c) superimposition of this model onto the 
intraoperative view of the patient provided by the robotic visual 
system. This third step is augmented reality: it is still undergoing 
intensive development but is currently capable of providing the 
surgeon with a superimposed transparent view of the patient’s 
internal anatomy, resulting in improved lesion targeting, 
improved ability to identify critical structures such as blood 
vessels that are not visible in the surgeon’s real field of view, and 
better tracking of instruments. Initially augmented reality relied 
on a non-modifiable virtual reality model of the patient – one 
that could not take organ deformation into account. However, the 
latest generation of augmented reality overcomes this limitation 
by using intraoperative 3D image acquisition and a non-rigid 
temporal registration algorithm (30).
The near future development of the technology is expected 
to involve “robotizing” the procedures or replacing many the 
surgeon’s maneuvers by automated or robotic maneuvers. This 
implies extensive further development, so that it will be able to 
give the real-time position and shape of organs, blood vessels, and 
diseased structures.
MeDicAL APPLicAtiONs OF rOBOts
The humanoid robot called Icube was developed at the Robotics 
Department of the Italian Institute of Technology (IIT). The devel-
opment of Icube and its sub-systems has driven, and continues 
to drive, advances in medical prosthetics and medical robotics. 
The robot is comparable in height to a 6-year-old child, which 
however would run all day on a bar of chocolate, while Icube 
would only last 10 min on that amount of energy. Furthermore, 
Icube only has a 2D brain; nonetheless, it is impressive. Its skin 
has over 4,000 contact points and sensors, so it can sense contact 
and contact forces and hence “understand” if it is being pulled 
or pushed and respond accordingly to maintain equilibrium. 
This haptic feedback system allows Icube to adapt and interact, 
allowing it to be a social humanoid. In fact, it has a vestibular 
system incorporating gyroscopes and sensors. The sensors are 
copied from nature. In nature, hair cells transform sounds (or 
mechanical vibrations in fish) into electric fields. The robot has 
the equivalent: Icube’s skin is made of a high technology plastic 
that is sensitive to tactile stimuli. For example, the skin is sensitive 
to being blown on, but it also transforms that “wind” energy – 
15 μW – into an electric current whose energy can be used. This 
secret of the plastic skin is that it incorporates conductive circuits 
made of graphene, which are printed onto the plastic using a 3D 
printer and graphene ink. Graphene is a Nobel-prize-winning 2D 
material that is cheap, ultra-light, 200 times stronger than steel, 
flexible, thin, transparent, and a superb conductor. Graphene ink 
is incorporated into sophisticated prostheses for amputees.
One example of such a prosthesis is a completely 3D-printed 
prosthetic hand with a single 9-W motor and a triple tendon 
system able to make 85% of the “grasps” of a human hand. It 
receives signals from muscle movement sensors on the patient’s 
arm and has an artificial intelligence system to translate signals 
into prosthetic hand movements (31). After only 2  months of 
rehabilitation and training, a patient can use the hand to perform 
manual work and execute fine movements. The hand currently 
costs 10,000 euro and is being tested on hundreds of patients.
Microtechnology and Systems for Robot-Assisted Laser 
Phonomicrosurgery is a European project coordinated by the IIT, 
which is enabling surgeons to better manipulate the cutting instru-
ment (laser scalpel) when performing vocal cord surgery. The 
fully integrated robot has a laser head and periscope controlled by 
high precision piezoelectric stage, with illumination. The surgeon 
wears an oculus to visualize the operating field from a laryngeal 
surgery endoscope. Magnification can be changed at will. Virtual 
reality is also projected by the oculus onto the surgeon’s field of 
view. Operating in virtual reality connected to a graph-pad with a 
pen, the surgeon uses the pen of the graph-pad to do what would 
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normally be done with the scalpel. The real laser scalpel can then 
be instructed to automatically make the cut planned by the sur-
geon on the graph-pad, with very high precision laterally (4 μm) 
and in depth (120 μm). Protected areas (blood vessels, nerves) can 
be defined. The latest robot for laryngeal microsurgery is called 
μRALP or micro-RALP (http://www.microralp.eu/).
The micro-robot called Plantoid is a novel robotic system that 
can “grow” into the body to reach a predetermined objective 
(like a root grows out from a plant into the soil) carrying with 
it sensors, biomarkers, or therapeutic agents. Plantoid grows in 
the “right” direction (avoiding critical structures) because it has 
sensors that allow it to avoid obstacles, hard surfaces, and high 
temperatures, etc. The tip is able to grow into the body to the 
desired target while remaining connected to its source outside the 
body, because the materials for growth are provided continuously 
as in 3D printing.
cONcLUsiON
Minimally invasive approaches to thoracic oncologic surgery are 
fast becoming mainstream. Large proportions of lobectomies in 
the United States and Europe (27), and increasing proportions of 
esophagectomies and thymectomies, are now being performed 
using these techniques. This contrasts with the situation in 2008 
when a survey of European surgeons found that nearly 60% of 
responders used VATS for lobectomy in less than 5% of cases 
(32) Thus, it would appear that the established advantages of 
minimally invasive over open surgery – particularly shorter hos-
pital stay, reduced long- and short-term morbidity, and at least 
equivalent oncological outcomes – are prompting the switch to 
VATS, notwithstanding its inherent difficulties for the surgeon.
Robotic thoracic surgery is also gaining in popularity. 
Surgeons who presented their experience at this Workshop were 
enthusiastic about robots and unanimous in their opinion that 
the robotic approach to the thorax was easier for the surgeon than 
VATS. The Workshop also highlighted current problems with 
robotic surgery, in particular high capital and running costs, and 
lack of high quality evidence that robotic surgery is superior to 
VATS in terms complications, conversion rates, and oncological 
radicality [although recent data suggest that robotic surgery is 
superior to VATS for mediastinal lymph node dissection (13)]. 
It is encouraging therefore that a multicentric randomized trial 
comparing robotic and VATS approaches to stages I and II lung 
cancer is about to start. Robotic surgery is a fast-developing field, 
and numerous innovations and improvements can be expected 
in the near future. Perhaps the most exciting of these is the use of 
modern imaging technology to produce augmented reality rep-
resentations of the patient’s anatomy, which can be superimposed 
onto the intraoperative view of the patient provided by the robotic 
visual system, to improve lesion targeting and identification of 
critical structures.
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